Literature DB >> 25902415

Defining high, medium and low impact prognostic factors for developing multiple sclerosis.

Mar Tintore1, Àlex Rovira2, Jordi Río3, Susana Otero-Romero3, Georgina Arrambide3, Carmen Tur3, Manuel Comabella3, Carlos Nos3, María Jesús Arévalo3, Laura Negrotto3, Ingrid Galán3, Angela Vidal-Jordana3, Joaquin Castilló3, Filipe Palavra3, Eva Simon3, Raquel Mitjana2, Cristina Auger2, Jaume Sastre-Garriga3, Xavier Montalban3.   

Abstract

Natural history studies have identified factors that predict evolution to multiple sclerosis or risk of disability accumulation over time. Although these studies are based on large multicentre cohorts with long follow-ups, they have limitations such as lack of standardized protocols, a retrospective data collection or lack of a systematic magnetic resonance imaging acquisition and analysis protocol, often resulting in failure to take magnetic resonance and oligoclonal bands into account as joint covariates in the prediction models. To overcome some of these limitations, the aim of our study was to identify and stratify baseline demographic, clinical, radiological and biological characteristics that might predict multiple sclerosis development and disability accumulation using a multivariate approach based on a large prospective cohort of patients with clinically isolated syndromes. From 1995 to 2013, 1058 patients with clinically isolated syndromes were included. We evaluated the influence of baseline prognostic factors on the risk for developing clinically definite multiple sclerosis, McDonald multiple sclerosis, and disability accumulation (Expanded Disability Status Scale score of 3.0) based on univariate (hazard ratio with 95% confidence intervals) and multivariate (adjusted hazard ratio with 95% confidence intervals) Cox regression models. We ultimately included 1015 patients followed for a mean of 81 (standard deviation = 57) months. Female/male ratio was 2.1. Females exhibited a similar risk of conversion to multiple sclerosis and of disability accumulation compared to males. Each younger decade at onset was associated with a greater risk of conversion to multiple sclerosis and with a protective effect on disability. Patients with optic neuritis had a lower risk of clinically definite multiple sclerosis [hazard ratio 0.6 (0.5-0.8)] and disability progression [hazard ratio 0.5 (0.3-0.8)]; however, this protective effect remained marginal only for disability [adjusted hazard ratio 0.6 (0.4-1.0)] in adjusted models. The presence of oligoclonal bands increased the risk of clinically definite multiple sclerosis [adjusted hazard ratio 1.3 (1.0-1.8)] and of disability [adjusted hazard ratio 2.0 (1.2-3.6)] independently of other factors. The presence of 10 or more brain lesions on magnetic resonance increased the risk of clinically definite multiple sclerosis [adjusted hazard ratio 11.3 (6.7-19.3)] and disability [adjusted hazard ratio 2.9 (1.4-6.0)]. Disease-modifying treatment before the second attack reduced the risk of McDonald multiple sclerosis [adjusted hazard ratio 0.6 (0.4-0.9)] and disability accumulation [adjusted hazard ratio 0.5 (0.3-0.9)]. We conclude that the demographic and topographic characteristics are low-impact prognostic factors, the presence of oligoclonal bands is a medium-impact prognostic factor, and the number of lesions on brain magnetic resonance is a high-impact prognostic factor.
© The Author (2015). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  clinically isolated syndromes; demyelination; epidemiology; imaging; multiple sclerosis

Mesh:

Substances:

Year:  2015        PMID: 25902415     DOI: 10.1093/brain/awv105

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  114 in total

Review 1.  Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis--establishing disease prognosis and monitoring patients.

Authors:  Mike P Wattjes; Àlex Rovira; David Miller; Tarek A Yousry; Maria P Sormani; Maria P de Stefano; Mar Tintoré; Cristina Auger; Carmen Tur; Massimo Filippi; Maria A Rocca; Franz Fazekas; Ludwig Kappos; Chris Polman
Journal:  Nat Rev Neurol       Date:  2015-09-15       Impact factor: 42.937

Review 2.  Treatment decisions in multiple sclerosis - insights from real-world observational studies.

Authors:  Maria Trojano; Mar Tintore; Xavier Montalban; Jan Hillert; Tomas Kalincik; Pietro Iaffaldano; Tim Spelman; Maria Pia Sormani; Helmut Butzkueven
Journal:  Nat Rev Neurol       Date:  2017-01-13       Impact factor: 42.937

3.  Different clinical response to interferon beta and glatiramer acetate related to the presence of oligoclonal IgM bands in CSF in multiple sclerosis patients.

Authors:  Bonaventura Casanova; Laura Lacruz; María Luisa Villar; José Andrés Domínguez; María Carcelén Gadea; Francisco Gascón; Javier Mallada; David Hervás; María Simó-Castelló; José Carlos Álvarez-Cermeño; Carmen Calles; Javier Olascoaga; Lluís Ramió-Torrentà; Carmen Alcalá; Angeles Cervelló; Isabel Boscá; Francisco Carlos Pérez-Mirallles; Francisco Coret
Journal:  Neurol Sci       Date:  2018-06-07       Impact factor: 3.307

Review 4.  Misdiagnosis of multiple sclerosis: Impact of the 2017 McDonald criteria on clinical practice.

Authors:  Andrew J Solomon; Robert T Naismith; Anne H Cross
Journal:  Neurology       Date:  2018-10-31       Impact factor: 9.910

Review 5.  Multiple sclerosis.

Authors:  Massimo Filippi; Amit Bar-Or; Fredrik Piehl; Paolo Preziosa; Alessandra Solari; Sandra Vukusic; Maria A Rocca
Journal:  Nat Rev Dis Primers       Date:  2018-11-08       Impact factor: 52.329

6.  High performance of cerebrospinal fluid immunoglobulin G analysis for diagnosis of multiple sclerosis.

Authors:  Simon Gamraoui; Guillaume Mathey; Marc Debouverie; Catherine Malaplate; René Anxionnat; Francis Guillemin; Jonathan Epstein
Journal:  J Neurol       Date:  2019-02-01       Impact factor: 4.849

7.  Intrathecal oligoclonal bands synthesis in multiple sclerosis: is it always a prognostic factor?

Authors:  Jessica Frau; Luisa Maria Villar; Claudia Sardu; Maria Antonietta Secci; Lucia Schirru; Diana Ferraro; Giancarlo Coghe; Lorena Lorefice; Giuseppe Fenu; Roberta Bedin; Patrizia Sola; Maria Giovanna Marrosu; Eleonora Cocco
Journal:  J Neurol       Date:  2017-12-22       Impact factor: 4.849

8.  Improved Automatic Detection of New T2 Lesions in Multiple Sclerosis Using Deformation Fields.

Authors:  M Cabezas; J F Corral; A Oliver; Y Díez; M Tintoré; C Auger; X Montalban; X Lladó; D Pareto; À Rovira
Journal:  AJNR Am J Neuroradiol       Date:  2016-06-09       Impact factor: 3.825

9.  SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts.

Authors:  Riley Bove; Tanuja Chitnis; Bruce Ac Cree; Mar Tintoré; Yvonne Naegelin; Bernard Mj Uitdehaag; Ludwig Kappos; Samia J Khoury; Xavier Montalban; Stephen L Hauser; Howard L Weiner
Journal:  Mult Scler       Date:  2017-08-29       Impact factor: 6.312

10.  Frequency and immunophenotype of IL10-producing regulatory B cells in optic neuritis.

Authors:  Sara Lundqvist; Signe Modvig; Emilie A Fischer; Jette L Frederiksen; Matilda Degn
Journal:  Immunology       Date:  2018-12-27       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.